Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9390
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSartor, Daniela Men
dc.contributor.authorVerberne, Anthony J Men
dc.date.accessioned2015-05-15T22:28:07Z
dc.date.available2015-05-15T22:28:07Z
dc.date.issued2002-04-01en
dc.identifier.citationAmerican Journal of Physiology. Regulatory, Integrative and Comparative Physiology; 282(4): R1174-84en
dc.identifier.govdoc11893623en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/9390en
dc.description.abstractCholecystokinin (CCK) is a potential mediator of gastrointestinal vasodilatation during digestion. To determine whether CCK influences sympathetic vasomotor function, we examined the effect of systemic CCK administration on mean arterial blood pressure (MAP), heart rate (HR), lumbar sympathetic nerve discharge (LSND), splanchnic sympathetic nerve discharge (SSND), and the discharge of presympathetic neurons of the rostral ventrolateral medulla (RVLM) in alpha-chloralose-anesthetized rats. CCK (1-8 microg/kg iv) reduced MAP, HR, and SSND and transiently increased LSND. Vagotomy abolished the effects of CCK on MAP and SSND as did the CCK-A receptor antagonist devazepide (0.5 mg/kg iv). The bradycardic effect of CCK was unaltered by vagotomy but abolished by devazepide. CCK increased superior mesenteric arterial conductance but did not alter iliac conductance. CCK inhibited a subpopulation (approximately 49%) of RVLM presympathetic neurons whereas approximately 28% of neurons tested were activated by CCK. The effects of CCK on RVLM neuronal discharge were blocked by devazepide. RVLM neurons inhibited by exogenous CCK acting via CCK-A receptors on vagal afferents may control sympathetic vasomotor outflow to the gastrointestinal tract vasculature.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherBradycardia.chemically induced.physiopathologyen
dc.subject.otherCholecystokinin.pharmacologyen
dc.subject.otherDevazepide.pharmacologyen
dc.subject.otherDigestive System.blood supplyen
dc.subject.otherHeart Rate.drug effectsen
dc.subject.otherHormone Antagonists.pharmacologyen
dc.subject.otherMaleen
dc.subject.otherMedulla Oblongata.cytology.drug effects.physiologyen
dc.subject.otherMotor Neurons.physiologyen
dc.subject.otherPeptide Fragments.pharmacologyen
dc.subject.otherRatsen
dc.subject.otherRats, Sprague-Dawleyen
dc.subject.otherReceptor, Cholecystokinin Aen
dc.subject.otherReceptors, Cholecystokinin.antagonists & inhibitorsen
dc.subject.otherSplanchnic Nerves.cytology.drug effects.physiologyen
dc.subject.otherSympathetic Nervous System.cytology.drug effects.physiologyen
dc.subject.otherVagotomyen
dc.subject.otherVagus Nerve.cytology.physiology.surgeryen
dc.titleCholecystokinin selectively affects presympathetic vasomotor neurons and sympathetic vasomotor outflow.en
dc.typeJournal Articleen
dc.identifier.journaltitleAmerican journal of physiology. Regulatory, integrative and comparative physiologyen
dc.identifier.affiliationClinical Pharmacology and Therapeutics Unit, Department of Medicine, Austin and Repatriation Medical Centre, University of Melbourne, Heidelberg, Victoria 3084, Australiaen
dc.identifier.doi10.1152/ajpregu.00500.2001en
dc.description.pagesR1174-84en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/11893623en
dc.type.austinJournal Articleen
local.name.researcherVerberne, Anthony J M
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptClinical Pharmacology and Therapeutics-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

42
checked on Feb 6, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.